Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

TBWA Paling Walters

- PMLiVE

Respiratory return helps GSK to solid first quarter

Seretide decline offset by gains for new-generation products Anoro, Breo and Nucala

- PMLiVE

Pfizer’s Champix and GSK’s Zyban cleared of causing neuropsychiatric side effects

EAGLES trial of 8,000 patients backs the smoking cessation drugs' safety

- PMLiVE

GSK’s morality gene

The firm is mutating in important ways - we should watch carefully

- PMLiVE

GSK gene therapy tops CHMP recommendations

ADA-SCID treatment Strimvelis set for European approval

- PMLiVE

GSK unveils access plan for low-income countries

Will file patents for its drugs according to each country’s 'economic maturity'

- PMLiVE

Japanese approvals for GSK, AZ and Bayer

MHLW gives Nucala, Tagrisso and Xofigo the green light

- PMLiVE

UK government fines GSK over ‘pay-for-delay’ deals

Merck KGaA and Actavis also fined for their involvement

- PMLiVE

Pharma trio join with top universities for new drug search

AZ, GSK and J&J join forces with Imperial, University College and Cambridge

- PMLiVE

Nucala price far too high for US market, says ICER

Concludes GlaxoSmithKline's new severe asthma therapy is not value for money

- PMLiVE

Amgen buys back product rights from GSK

Prolia, Xgeva and Vectibix brought back in-house

- PMLiVE

Mixed news for gene therapies at ASH conference

GSK unveils successful trial, but there was disappointing news for Bluebird

- PMLiVE

GSK earns expanded approval for Volibris in Europe

Additional indication given to pulmonary arterial hypertension drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links